Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

NCAM (CD56)-positive malignant lymphoma

W F Kern¹, C M Spier, T P Miller

¹Department of Pathology, Arizona Cancer Center, Tucson.

Leukemia & Lymphoma

|December 1, 1993

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prediction of Outcome in Diffuse Large Cell Lymphoma by the Major Histocompatibility Complex Class II (HLA-DR, DP, DQ) and Class I (HLA-A, B, C) Phenotype.

Leukemia & lymphoma·2016

Same author

A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213.

Annals of oncology : official journal of the European Society for Medical Oncology·2013

Same author

Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices.

Annals of oncology : official journal of the European Society for Medical Oncology·2012

Same author

Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas.

Annals of oncology : official journal of the European Society for Medical Oncology·2012

Same author

Stromal gene signatures in large-B-cell lymphomas.

The New England journal of medicine·2008

Same author

Chromosomal changes detected by fluorescence in situ hybridization in patients with acute lymphoblastic leukemia.

Chinese medical journal·2003

Neural cell adhesion molecule (NCAM) CD56 identifies aggressive lymphomas. NCAM-positive lymphomas show frequent unusual site involvement and a more aggressive clinical course, indicating biological and clinical significance.

Area of Science:

Immunology
Oncology
Cell Biology

Background:

Neural cell adhesion molecule (NCAM) is an immunoglobulin superfamily member involved in cell adhesion.
NCAM contains polysialic acid, regulating binding avidity and cell adhesion processes.
NCAM is related to leukocyte antigens and cell adhesion molecules implicated in neoplasms.

Purpose of the Study:

To investigate the biological and clinical significance of NCAM in lymphomas.
To determine if NCAM expression correlates with tumor behavior and spread.

Main Methods:

Identification of NCAM-positive lymphomas.
Comparison of NCAM-positive and NCAM-negative lymphoma groups.
Analysis of clinical data including site involvement and disease course.

Related Experiment Videos

Main Results:

NCAM-positive lymphomas frequently involved unusual sites.
NCAM-positive lymphomas exhibited a generally aggressive clinical course.
A separate series of CD56-positive hematolymphoid malignancies also showed unusual site involvement and aggressive behavior.

Conclusions:

NCAM expression on lymphoma is biologically and clinically significant.
NCAM positivity is associated with altered tumor behavior and spread patterns.
NCAM may serve as a prognostic marker in hematolymphoid malignancies.